From the 2022 AUA guidelines:
Clinicians should inform patients with intermediate-risk prostate cancer considering whole gland or focal ablation that there are a lack of high-quality data comparing ablation outcomes to radiation therapy, surgery, and active surveillance. (Expert Opinion)PS: Relevant information about
your case would be helpful.
Post Edited (Sr Sailor) : 10/14/2022 7:50:13 PM (GMT-7)